Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
19 studies found for:    "Leber hereditary optic neuropathy" OR "Hereditary Optic Atrophy"
Show Display Options
Rank Status Study
1 Completed
Has Results
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
Condition: Leber Hereditary Optic Neuropathy
Intervention: Drug: rAAV2-ND4
2 Completed Study to Assess Efficacy,Safety and Tolerability of Idebenone in the Treatment of Leber's Hereditary Optic Neuropathy
Condition: Leber's Hereditary Optic Neuropathy
Interventions: Drug: Idebenone;   Drug: Placebo
3 No longer available Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]
Condition: Leber's Hereditary Optic Neuropathy
Intervention: Drug: EPI-743
4 Active, not recruiting Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients
Condition: Leber Hereditary Optic Neuropathy
Intervention: Genetic: GS010
5 Recruiting Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy
Condition: Leber's Hereditary Optic Neuropathy
Interventions: Drug: injection of scAAV2-P1ND4v2 5.00x10e9 vg (Low),;   Drug: injection of scAAV2-P1ND4v2 2.46X10e10 vg (Med);   Drug: injection of scAAV2-P1ND4v2 1.0X10e11vg (High)
6 Recruiting A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution for the Treatment of Leber's Hereditary Optic Neuropathy
Condition: Leber's Hereditary Optic Neuropathy
Interventions: Drug: elamipretide (MTP-131) 1% topical ophthalmic solution;   Drug: Vehicle topical ophthalmic solution
7 Terminated
Has Results
Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON)
Condition: Leber's Hereditary Optic Neuropathy (LHON)
Intervention: Device: Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))
8 Recruiting Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)
Condition: Leber's Hereditary Optic Neuropathy (LHON)
Intervention:
9 Completed RHODOS Follow-up Single-visit Study
Condition: Leber's Hereditary Optic Neuropathy
Intervention:
10 Unknown  Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy
Condition: Leber Hereditary Optic Neuropathy
Intervention: Drug: cyclosporine
11 Withdrawn Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)
Condition: Leber's Hereditary Optic Neuropathy
Interventions: Drug: Idebenone;   Drug: Placebo
12 Completed Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey
Condition: Leber Hereditary Optic Neuropathy (LHON)
Intervention:
13 Not yet recruiting Post Authorisation Safety Study With Raxone in LHON Patients
Condition: Leber's Hereditary Optic Neuropathy (LHON)
Intervention: Drug: Idebenone
14 Recruiting Study to Assess the Efficacy and Safety of Raxone in LHON Patients
Condition: Leber's Hereditary Optic Neuropathy (LHON)
Intervention: Drug: Idebenone
15 Completed A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON)
Condition: Optic Atrophy, Hereditary, Leber
Intervention: Drug: curcumin
16 Recruiting Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation
Condition: Optic, Atrophy, Hereditary, Leber
Interventions: Genetic: GS010;   Other: Sham Intravitreal Injection
17 Recruiting Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation
Condition: Optic, Atrophy, Hereditary, Leber
Interventions: Genetic: GS010;   Other: Sham Intravitreal Injection
18 Enrolling by invitation Open-Label, Dose-Escalating Study to Assess Safety, Tolerability, Efficacy, PK and PD of RP103 in Children With Inherited Mitochondrial Disease
Condition: Inherited Mitochondrial Disease, Including Leigh Syndrome
Intervention: Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
19 Completed Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
Conditions: Optic Atrophy;   Non-arteritic Anterior Ischemic Optic Neuropathy
Intervention: Drug: QPI-1007 at various doses

Study has passed its completion date and status has not been verified in more than two years.